OraSure Technologies (NASDAQ:OSUR) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened

OraSure Technologies, Inc. (NASDAQ:OSUR) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.18 and traded as high as $4.40. OraSure Technologies shares last traded at $4.32, with a volume of 496,215 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Stock Up 0.7%

The business’s fifty day moving average is $3.85 and its two-hundred day moving average is $3.21. The stock has a market capitalization of $294.67 million, a PE ratio of -4.12 and a beta of 1.01.

Insider Buying and Selling

In other OraSure Technologies news, Director Steven Kyle Boyd acquired 25,000 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was acquired at an average cost of $2.99 per share, with a total value of $74,750.00. Following the purchase, the director directly owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. This represents a 28.26% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new stake in OraSure Technologies during the fourth quarter worth approximately $28,000. Prudential Financial Inc. purchased a new stake in OraSure Technologies during the 2nd quarter valued at $31,000. Diversify Wealth Management LLC purchased a new stake in OraSure Technologies during the 1st quarter valued at $36,000. Amundi bought a new stake in OraSure Technologies in the first quarter worth $47,000. Finally, SG Americas Securities LLC lifted its position in OraSure Technologies by 77.7% in the fourth quarter. SG Americas Securities LLC now owns 19,748 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 8,632 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.